The researches find that the developing a user-friendly (worn at home) vest with technology that collects data to tailor personalized therapy for patients with metastatic, somatostatin-receptor-2 positive neuroendocrine tumors (NETs). The study is present at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Tailor personalized therapy
Targeted therapy using lutetium-177 (177Lu)-DOTATATE greatly increases progression-free survival for NETs patients. While approved by the United States Food and Drug Administration (FDA); the FDA package instructions call for patients to receive a standardize protocol, regardless of size or weight. Traditionally, targeted radionuclide therapies are personalize based on dose to the main organs at risk (OAR, e.g., kidneys, liver, spleen).
“Organ specific dosimetry for the 177Lu-DOTATATE (Lutathera); is the norm at many medical centers outside of the United States;” explains Robert Miyaoka at the University of Washington. “Longitudinal imaging studies are conduct after each therapy treatment to determine the cumulative dose to the OAR for each patient. The standardized 177Lu-DOTATATE treatment protocol in the United States consists of four 200 mCi doses spaced two months apart.
Although this is safe for a vast majority of patients, it is less than optimal for most. Studies out of Europe are revealing that tailoring the number of treatment doses based upon the dose-limiting toxicity to the patient’s OAR can more than double the progression-free and overall survival for NET patients undergoing 177Lu-DOTATATE therapy.”
Another factor the researchers sought to address is the fact that traditional imaging-base methods for organ dosimetry estimation for 177Lu require three-to-four longitudinal imaging sessions spread over seven days. This is expensive; uses a lot of clinic resources and is burdensome to the patient.
“They propose to create a lightweight, low-cost; wearable, patient-specific technology that will allow organ-specific measurement recordings to be made within the comfort of the patient’s home;” Miyaoka says. “The garment [called a multi-detector personalized home dosimetry (MD PHD) vest] will house 15-20 small radiation detectors; strategically placed within the vest based upon the patient’s own anatomy.
In addition to the radiation detectors the vest will be coupled to a compact electronics pack that will acquire the data and send it via WiFi or cellular services to a secure website where medical personnel/software can check the data for quality control in near real-time.”He further explains; “The patient will be asked to wear the vest for a two-minute data acquisition once a day for seven (and up to 21) days. Based upon these at-home measurements and a single SPECT/CT image taken 24 hours after the therapy administration; organ specific dosimetry will be determined for all of the patient’s OAR.